← All trials
NCT05740371
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 18, 2017
- Primary completion
- May 6, 2021
- Completion date
- May 6, 2021
- First posted
- Feb 23, 2023
- Last posted
- Feb 27, 2023
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Mitsubishi TanabeLead sponsor
- Mitsubishi TanabeStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.